ISMICS Home  |  Past & Future Meetings
Countdown to ISMICS : -38 Days  
International Society For Minimally Invasive Cardiothoracic Surgery

Back to 2020 ePosters


Transcatheter Caval Valve Implantation For Tricuspid Valve Regurgitation; A New Frontier
Seyed Hossein Aalaei-Andabili, Anthony Bavry, Hussam Hawamdeh, Eric Jeng, George Arnaoutakis, Thomas Beaver.
University of Florida, Gainesville, FL, USA.

Background: Severe tricuspid valve regurgitation (TR) leads to decreased cardiac output and devastating functional incapacity. Transcatheter aortic valve options are limited for the tricuspid valve; however, novel technology allows treatment of the upstream effects of severe TR by placing a transcatheter valve into the stented suprahepatic inferior vena cava (IVC). We report transcatheter valve implantation into the dilated IVC of patients with end stage severe tricuspid valve regurgitation. Methods: From September 2018 to October 2019, 4 inoperable patients with severe tricuspid valve regurgitation who had failed medical treatment underwent percutaneous caval valve implantation (CAVI). Severity of tricuspid regurgitation was confirmed by intra-operative transesophageal echocardiography. Two Z-stents (Cook, Inc., Bloomington, IN) were placed in the suprahepatic IVC and then a transcatheter valve was deployed within the stented IVC just above the hepatic vein without rapid pacing. Results: Four patients, 1 female and 3 males with meanąSD age of 77.2ą7.3 years were included. The procedure was successfully performed in all 4 patients (100%) employing a 29 mm SAPIEN 3 valve (Edwards Lifesciences, Irvine, CA). No complications occurred during or after the procedure. Within 30-days, tricuspid valve regurgitation improved from severe to mild-moderate in 2 patients. Among patients with improved TR, ejection fraction increased from 55-60% to 65-70%. No patient had readmission within 30-days. Conclusions: Percutaneous caval valve implantation (CAVI) is feasible with zero morbidity and can be considered as a palliative measure in patients with severe tricuspid valve regurgitation. CAVI can improve TR and cardiac output and potentially improves diuretic responsiveness by lowering venous hypertension. Further studies with a larger sample size and longer-term follow up is warranted to evaluate the efficacy and durability of CAVI.


Back to 2020 ePosters
Poland
Poland
Poland
Poland
By using this site, you agree to our updated Privacy Policy.  Got it